# Invaplex 50 Vaccine Dose-Ranging

> **NCT00082069** · PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 32 (actual)

## Conditions studied

- Diarrhea

## Interventions

- **BIOLOGICAL:** Shigella flexneri 2a Invaplex 50

## Key facts

- **NCT ID:** NCT00082069
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082069, "Invaplex 50 Vaccine Dose-Ranging". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00082069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*